Daphne Wu

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

K.N. Chi, Shahneen Sandhu, Matthew R. Smith et al. · Annals of Oncology · 2023 · 199 citations · Full text

Medicine, Oncology, Urology +17

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2022 · 125 citations

Medicine, Oncology, Pharmacology +16

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Fred Saad, Eleni Efstathiou, Gerhardt Attard et al. · The Lancet Oncology · 2021 · 106 citations · Full text

Medicine, Oncology, Urology +16

Reductions in smoking due to ratification of the Framework Convention for Tobacco Control in 171 countries

Guillermo Paraje, Mauricio Flores Muñoz, Daphne Wu et al. · Nature Medicine · 2024 · 50 citations · Full text

Public Health, Health Policy, Preventive Medicine +17